Research Article
Fibrosis-4 Model Influences Results of Patients with Hepatocellular Carcinoma Undergoing Hepatectomy
Table 4
Characteristics of the included patients with fibrosis-4<3.15 and fibrosis-4⩾3.15.
| | Parameters | Fibrosis-4 <3.15 | Fibrosis-4 ⩾3.15 | P value | | (N=477) | (N=311) |
| | Male (%) | 411 (86.2%) | 257 (82.6%) | 0.188 | | Age (years) (Mean ± SD) | 47.7±11.7 | 56.3±10.4 | <0.01 | | Etiology | | | | | HBV (%) | 397 (83.2%) | 268 (86.2%) | 0.272 | | HCV (%) | 5 (1.0%) | 9 (2.9%) | 0.094 | | NBNC (%) | 81 (17.0%) | 44 (14.1%) | 0.319 | | Child Grade | | | 0.037 | | A (%) | 458 (96.0%) | 288 (92.6%) | | | B (%) | 19 (4.0%) | 23 (7.4%) | |
| | MELD, median (IQR) | 8 (7-10) | 9 (7-10) | 0.001 | | AST (U/L) (Mean ± SD) | 39.9±18.5 | 68.4±52.7 | <0.01 | | ALT (U/L) (Mean ± SD) | 44.5±26.8 | 58.1±54.6 | <0.01 | | Total bilirubin (umol/L) (Mean ± SD) | 15.5±16.2 | 17.3±8.5 | 0.06 | | Albumin (g/L) (Mean ± SD) | 41.5±4.2 | 40.7±4.7 | 0.035 | | INR (Mean ± SD) | 1.26±0.14 | 1.31±0.15 | <0.01 | | PLT (109/L) (Mean ± SD) | 170.2±67.7 | 94.2±43.6 | <0.01 | | Ishak | | | <0.01 | | 0-2 (%) | 265 (55.6%) | 17 (5.5%) | | | 3-4 (%) | 83 (17.4%) | 12 (3.9%) | | | 5-6 (%) | 129 (27.0%) | 282 (90.7%) | | | Cirrhosis (%) | 129 (27.0%) | 282 (90.7%) | <0.01 | | AFP (ng/mL) median (IQR) | 315 (9.5-1210) | 140 (8.6-1210) | 0.24 | | BCLC | | | 0.082 | | 0-A (%) | 328 (68.8%) | 209 (67.2%) | | | B (%) | 61 (12.8%) | 56 (18%) | | | C (%) | 88 (18.4%) | 46 (14.8%) | | | Tumor | | | 0.355 | | Single (%) | 390 (81.8%) | 246 (79.1%) | | | Multiple (%) | 87 (18.2%) | 65 (20.9%) | | | Macrovascular invasion (%) | 59 (12.4%) | 34 (10.9%) | 0.541 | | Microvascular Invasive (%) | 98 (20.5%) | 64 (20.6%) | 0.991 | | Differentiation Degree | | | 0.674 | | Poor (%) | 56 (11.7%) | 33 (10.6%) | | | Moderate (%) | 408 (85.5%) | 272 (87.5%) | | | Well (%) | 13 (2.7%) | 6 (1.9%) | | | Recurrent Hepatocellular Carcinoma (%) | 19 (4.0%) | 18 (5.8%) | 0.242 | | Complications III-V (%) | 36 (7.5%) | 32 (10.3) | 0.180 | | Hepatic Insufficiency (%) | 30 (6.3%) | 37 (11.9%) | 0.006 | | Transfusion (%) | 101 (21.2%) | 74 (23.8%) | 0.387 | | Hospital Stay (days) median (IQR) | 8 (7-10) | 9 (7-11) | <0.01 |
|
|
ALT: alanine aminotransferase; AST: aspartate aminotransferase. AFP: α-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; INR: international normalized ratio; PLT: platelet count. APRI: AST-to-platelet ratio index; HBV: hepatitis B virus; HCV: hepatitis C virus; NBNC: non-B non-C hepatitis virus. IQR: interquartile range; SD: standard deviation.
|
